Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T17:56:53.077Z.
Calculation as of: 2026-10-06T17:56:53.077Z.
Quote observation: 2026-10-06T17:55:15.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 767633254d5919bd59cda52a5696942c7bb29bc9076435c5b91744fa0c767718
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Werewolf Therapeutics, Inc.
Market Cap
$45.20M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$43.88M
EV/EBITDA Ratio
N/A
TTM Avg
14.42x
3Y Avg
17.44x
5Y Avg
22.72x
Market Cap
$43.92M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$43.38M
EV/EBITDA Ratio
23.59x
TTM Avg
28.58x
3Y Avg
33.75x
5Y Avg
33.75x
Market Cap
$48.05M
EV/EBITDA Ratio
N/A
TTM Avg
119.16x
3Y Avg
119.16x
5Y Avg
119.16x
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Werewolf Therapeutics, Inc. (HOWL) | $45.20M | N/A | N/A | N/A | N/A |
| CVRx, Inc. (CVRX)vs › | $44.45M | N/A | N/A | N/A | N/A |
| DarioHealth Corp. (DRIO)vs › | $43.88M | N/A | 14.42x | 17.44x | 22.72x |
| Rapid Micro Biosystems, Inc. (RPID)vs › | $43.92M | N/A | N/A | N/A | N/A |
| Nano-X Imaging Ltd. (NNOX)vs › | $43.59M | N/A | N/A | N/A | N/A |
| SANUWAVE Health Inc. (SNWV)vs › | $43.38M | 23.59x | 28.58x | 33.75x | 33.75x |
| Instil Bio, Inc. (TIL)vs › | $47.27M | N/A | N/A | N/A | N/A |
| Precision Optics Corporation, Inc. (POCI)vs › | $48.05M | N/A | 119.16x | 119.16x | 119.16x |
| Lite Strategy, Inc. (LITS)vs › | $48.15M | N/A | N/A | N/A | N/A |
| BioStem Technologies, Inc. (BSEM)vs › | $43.22M | N/A | 7.89x | 10.87x | 10.87x |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
